A Phase I, Dose Escalation Study to Assess the Safety & Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer.
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Doxorubicin liposomal; Iboctadekin
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker
- 31 Aug 2018 Biomarkers information updated
- 25 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.